← 返回首页
美国 · 通讯社与实时数据 · PR Newswire

Protego Presents New Data at ISA 2026 that Advances Evidence for Light-Chain Stabilization with PROT-001 in AL Amyloidosis

来源:PR Newswire · 美国 22 分钟前
Protego Presents New Data at ISA 2026 that Advances Evidence for Light-Chain Stabilization with PROT-001 in AL Amyloidosis
PR Newswire

详细摘要

- PROT-001, the company's investigational oral small molecule drug for AL amyloidosis, demonstrated an acceptable safety and tolerability profile in a healthy volunteer Phase 1…

- In human cardiomyocyte and plasma cell studies, PROT-001 reduced markers of stress and toxicity, and demonstrated compatibility with standard-of-care bortezomib

- Additional presentations highlight advanced detection of amyloidogenic light chains with Protego's AmyLiteDxTM assay, and use of NT-proBNP as an early clinical biomarker of cardiac response

- Results support evaluating PROT-001 in planned Phase 2/3 SHIELD-AL study in AL amyloidosis patients

SAN DIEGO, Nov. 16, 2026 /PRNewswire/ -- Protego Biopharma, Inc., a clinical-stage biotechnology company developing small-molecule therapies for protein misfolding diseases, today announced results from five presentations that highlight the Phase I clinical and preclinical profile of PROT-001, the company's potential first-in-class, investigational lambda light chain kinetic stabilizer to treat light chain (AL) amyloidosis.

PROT-001 is designed as a kinetic stabilizer of amyloidogenic light chains (LCs) and to neutralize their toxicity. Across the five ISA 2026 presentations, Protego presented data that, collectively, support the advancement of PROT-001 into pivotal studies.

"Cardiac involvement is a major driver of morbidity and mortality in AL amyloidosis. Plasma cell-directed therapies reduce the production of light chains, but circulating amyloidogenic light chains can continue to damage the heart," said Brent J. Warner, MBA, Chief Executive Officer of Protego. "PROT-001 is designed to complement these treatments by stabilizing amyloidogenic light chains and reducing their toxicity. The data presented at ISA 2026 strengthen the rationale for SHIELD-AL, where we will evaluate whether this approach can deliver earlier and deeper cardiac responses."

Detailed results from Protego's five poster presentations are as follows:

PROT-001, a first-in-class lambda light chain kinetic stabilizer for AL amyloidosis: Results from the Phase I PRO-1A-101 Study (Abstract 32458)PRO-1A-101 evaluated the safety, tolerability…

In the study…

文章开头,摘自PR Newswire。如需阅读全文,请前往媒体网站。

在 PR Newswire 阅读全文 登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.prnewswire.com)

推荐阅读